A 72-year-old woman with a 15-year history of CKD stage 4 (eGFR 18 mL/min/1.73m²) secondary to hypertensive nephrosclerosis presents with nausea, poor appetite, and a 3 kg weight loss over 2 months. She is on lisinopril 10 mg daily, amlodipine 5 mg daily, and atorvastatin. Recent labs: serum creatinine 3.6 mg/dL, potassium 5.8 mEq/L, phosphate 5.2 mg/dL, calcium 7.8 mg/dL, albumin 3.1 g/dL, and hemoglobin 9.2 g/dL. Urinalysis shows 1+ protein, no casts. Which of the following is the MOST important intervention to prevent progression to ESRD and reduce mortality in this patient?

Explanation

## Clinical Context This patient has advanced CKD stage 4 with evidence of mineral-bone disorder (hyperphosphatemia, hypocalcemia), malnutrition (low albumin, weight loss), and mild hyperkalemia. She is approaching ESRD and requires comprehensive renoprotective and metabolic management. ## Rationale for Correct Answer **Key Point:** Finerenone, a novel non-steroidal mineralocorticoid receptor antagonist (MRA), has demonstrated in the FIDELITY trial that it reduces CKD progression, cardiovascular events, and mortality in advanced CKD (stages 3–4) with or without diabetes, independent of blood pressure lowering. **High-Yield:** Finerenone differs from spironolactone: - Does NOT cause hyperkalemia (critical in CKD stage 4) - Reduces proteinuria and inflammation - Proven mortality benefit in CKD stage 4 - Can be safely combined with ACE-I/ARB **Clinical Pearl:** Phosphate control is essential in CKD stage 4 to prevent secondary hyperparathyroidism and vascular calcification. Dietary phosphate restriction + phosphate binders (calcium-free binders preferred in hypocalcemia) reduce FGF23 and slow CKD progression. ## Mineral-Bone Disorder Management | Parameter | Target | Intervention | |-----------|--------|-------------| | Phosphate | 3.5–5.5 mg/dL | Dietary restriction, binders (sevelamer), consider calcitriol if PTH elevated | | Calcium | 8.5–10.5 mg/dL | Avoid calcium binders; use calcitriol if hypocalcemic | | PTH | 150–300 pg/mL (CKD-4) | Monitor; treat secondary hyperparathyroidism | [cite:KDIGO 2017 CKD-MBD Guidelines]